Debate on long-acting β agonists for asthma: they think it's all over

Brian Lipworth; Sunny Jabbal

doi:10.1016/S2213-2600(17)30053-X

Debate on long-acting β agonists for asthma: they think it's all over

Brian Lipworth (Lead / Corresponding author)
, Sunny Jabbal

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

296 Downloads (Pure)

Abstract

At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?

Original language	English
Pages (from-to)	e14-e15
Number of pages	2
Journal	The Lancet Respiratory Medicine
Volume	5
Issue number	3
Early online date	28 Feb 2017
DOIs	https://doi.org/10.1016/S2213-2600(17)30053-X
Publication status	Published - Mar 2017

Keywords

Letter

Access to Document

10.1016/S2213-2600(17)30053-X

Author Accepted Manuscript
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 121 KBLicence: CC BY-NC-ND

Cite this

@article{01481158349341b3bcd7824c620c413a,

title = "Debate on long-acting β agonists for asthma: they think it's all over",

abstract = "At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone{\textendash}salmeterol or budesonide{\textendash}formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS{\textendash}LABA combination inhalers with impunity at step 3 and above of asthma guidelines?",

keywords = "Letter",

author = "Brian Lipworth and Sunny Jabbal",

note = "BL reports grants and personal fees from Teva, Boehringer Ingelheim, Meda, and Chiesi Pharma; personal fees from Dr Reddy's, Sandoz, and Lupin; grants from AstraZeneca, Janssen, Roche, and Sanofi; and other support from Napp, outside of the submitted work. SJ reports personal fees and non-financial support from Chiesi Pharma, non-financial support from Pfizer and Napp, and other support from Napp, outside of the submitted work.",

year = "2017",

month = mar,

doi = "10.1016/S2213-2600(17)30053-X",

language = "English",

volume = "5",

pages = "e14--e15",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Debate on long-acting β agonists for asthma

T2 - they think it's all over

AU - Lipworth, Brian

AU - Jabbal, Sunny

N1 - BL reports grants and personal fees from Teva, Boehringer Ingelheim, Meda, and Chiesi Pharma; personal fees from Dr Reddy's, Sandoz, and Lupin; grants from AstraZeneca, Janssen, Roche, and Sanofi; and other support from Napp, outside of the submitted work. SJ reports personal fees and non-financial support from Chiesi Pharma, non-financial support from Pfizer and Napp, and other support from Napp, outside of the submitted work.

PY - 2017/3

Y1 - 2017/3

N2 - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?

AB - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?

KW - Letter

U2 - 10.1016/S2213-2600(17)30053-X

DO - 10.1016/S2213-2600(17)30053-X

M3 - Letter

C2 - 28266330

SN - 2213-2600

VL - 5

SP - e14-e15

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 3

ER -

Debate on long-acting β agonists for asthma: they think it's all over

Abstract

Keywords

Access to Document

Fingerprint

Cite this